Mutations in the RAS and RAF family of oncogenes have been detected in a significant percentage (15 and 50%, respectively) of human melanoma patients (1, 12), leading to the development of BRAF and MEK inhibitors as potential therapeutic agents (5). This evidence concerns the gene MAP2K7 and melanoma.